Target Name: ACRV1
NCBI ID: G56
Other Name(s): OTTHUMP00000231310 | SPACA2 | ACRV1 variant 1 | ASPX_HUMAN | D11S4365 | SP-10 | Acrosomal protein SP-10 | Acrosomal vesicle protein 1 | Acrosomal vesicle protein 1, transcript variant 1 | acrosomal vesicle protein 1 | Acrosomal protein SP-10 (isoform a) | OTTHUMP00000231312 | sperm protein 10 | OTTHUMP00000231313 | OTTHUMP00000231311 | Sperm protein 10

ACRV1: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with a high incidence and poor prognosis. Despite advances in surgical and radiation treatments, the survival rate for advanced ovarian cancer remains poor, and the disease remains a significant public health burden. Therefore, identifying potential drug targets and biomarkers for ovarian cancer is of great interest.

ACRV1: A Potential Drug Target

The ACRV1 gene is a potential drug target for ovarian cancer. It is a gene that encodes a protein known as activator of cell death (ACRV1), which is involved in cell signaling pathways, including the T-cell signaling pathway. The T-cell signaling pathway is involved in immune surveillance, and it plays a crucial role in fighting off cancer cells.

Studies have shown that ACRV1 is highly expressed in ovarian cancer tissues and that it is involved in the development and progression of ovarian cancer. Additionally, inhibition of ACRV1 has been shown to enhance the effectiveness of anti-ovarian cancer treatments.

ACRV1 as a Biomarker

One of the challenges in the treatment of ovarian cancer is the lack of biomarkers that can be used to predict the outcomes of patients and guide treatment decisions. However, ACRV1 may be a valuable biomarker for ovarian cancer.

Studies have shown that ACRV1 expression is associated with poor prognosis in ovarian cancer patients. Additionally, high ACRV1 expression has been shown to be associated with poor response to chemotherapy in ovarian cancer patients.

Conclusion

In conclusion, ACRV1 is a potential drug target and biomarker for ovarian cancer. Its involvement in the T-cell signaling pathway and its association with poor prognosis and poor response to chemotherapy make it an attractive target for cancer researchers. Further studies are needed to confirm its potential as a drug target and biomarker in ovarian cancer.

Protein Name: Acrosomal Vesicle Protein 1

More Common Targets

ACSBG1 | ACSBG2 | ACSF2 | ACSF3 | ACSL1 | ACSL3 | ACSL4 | ACSL5 | ACSL6 | ACSM1 | ACSM2A | ACSM2B | ACSM3 | ACSM4 | ACSM5 | ACSM6 | ACSS1 | ACSS2 | ACSS3 | ACTA1 | ACTA2 | ACTA2-AS1 | ACTB | ACTBL2 | ACTBP12 | ACTBP2 | ACTBP3 | ACTBP8 | ACTBP9 | ACTC1 | ACTE1P | ACTG1 | ACTG1P1 | ACTG1P10 | ACTG1P12 | ACTG1P17 | ACTG1P20 | ACTG1P22 | ACTG1P25 | ACTG1P4 | ACTG2 | Actin | Activating signal cointegrator 1 complex protein | Activin receptor type 2 (nonspecifed subtype) | ACTL10 | ACTL6A | ACTL6B | ACTL7A | ACTL7B | ACTL8 | ACTL9 | ACTMAP | ACTN1 | ACTN1-DT | ACTN2 | ACTN3 | ACTN4 | ACTR10 | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACTR3B | ACTR3BP2 | ACTR3BP5 | ACTR3BP6 | ACTR3C | ACTR5 | ACTR6 | ACTR8 | ACTRT1 | ACTRT2 | ACTRT3 | ACVR1 | ACVR1B | ACVR1C | ACVR2A | ACVR2B | ACVR2B-AS1 | ACVRL1 | ACY1 | ACY3 | Acyl-CoA dehydrogenase (ACAD) | Acyl-CoA Synthetase Short-Chain | ACYP1 | ACYP2 | ADA | ADA2 | ADA2A-containing complex (ATAC) | ADAD1 | ADAD2 | ADAL | ADAM10 | ADAM11 | ADAM12 | ADAM15 | ADAM17 | ADAM18 | ADAM19 | ADAM1A